The National Methadone Conference-5

American Association for the Treatment of Opioid Dependence
Washington, D.C. ~ April 13-16, 2003


Session: Workshop
April 15, 2003

Medication – Assisted Treatment in Different Practice Settings: Patients’ Perspectives

Joycelyn Woods, National Alliance of Methadone Advocates, Facilitator

NAMA representativees will discuss the administration of methadone in a variety of settings. Topics will include the patients’ perspective on which elements of practice contribute to a positive treatment setting and how common terminology used to describe treatment and patients is expected to change as methadone begins to be offered in more mainstream settings.
Basic Track

Methadone and Ibogaine: A Historical Comparison of Patient Status and Advocacy Issues
Howard Lotsof, Membership Director
National Alliance of Methadone Advocates
Dora Weiner Organization

A Retrospective

Though methadone, an opioid agonist therapy and ibogaine, a substance having diverse complex mechanisms of actions appear quite different in their effects both medications have strong patient advocacy support. With the two medications being so distinct in their dose regimen and treatment profile it is interesting to note the advantages of early generation patients of each modality and the power they held compared to later generations of patients.

Within the methadone context this special status of early patients, many of whom became Research Assistants (RAs) was directly attributable to the two doctors responsible for the development of methadone maintenance, Drs. Vincent Dole and Marie Nyswander. Ibogaine provides a somewhat different scenario wherein the medication’s discovery as an antiaddictive agent came from the drug using counter culture. As ibogaine was lead into formal regulatory development by its discoverer, Howard S. Lotsof, he maintained a strong working relationship with patients and patient advocates who were immediately incorporated into early research through the International Coalition for Addict Self-help (ICASH) founded by Robert Sisko and Dutch Addict Self-help (DASH), established by N.F.P. Adriaans, G. Frenken and their associates.

As methadone moved further and further from its Dole/Nyswander beginning, providers became repressive and controlling towards their patients with strong antipatient and antiadvocacy positions taken within clinics to which methadone distribution was restricted. It should be noted that there are exceptions and that agencies within the federal government as well as, private groups and some methadone clinics themselves have recognized the detrimental effects associated with stigma and prejudice towards patients and are now beginning to attempt to reverse these conditions that are not conducive to recovery or the benefit of patients.

Ibogaine has not moved that far from its roots and we do not yet see the biased treatment of patients nor the ability to control them in a manner associated with methadone clinics. However, the patients themselves appear to have little direct access to ibogaine and to no longer participate in its administration to other patients in therapeutic self-help environments. While Lotsof believes that the ibogaine community can return to a situation closely identified with the patient/provider relationship similar to the golden age of methadone, Dr. Dole, the father of methadone maintenance therapy believes that the return to such practices for methadone itself will not be possible.

This project of the Dora Weiner OrganizationDora Weiner Foundation (DWF) is to document in reports and photographs the early generation of patients and advocates within both the ibogaine and methadone community for historical comparison in the hope that we may improve the lives of current patients through an understanding of the past.

Methadone and Ibogaine: A Historical Comparison of Patient Status and Advocacy Issues.(powerpoint)
Manual Handout

Pain Management and the Methadone Patient
James Connolly, Regional Director
National Alliance of Methadone Advocates
Pennsylvania NAMA

(To Be Available)

Words That Hurt: How the words that are used promote stigma
Roxanne Baker, Chapter Coordinator
National Alliance of Methadone Advocates
NAMA NorCal

(To Be Available)

Similar Posts

  • Tag: patient rights

    Admin 11/08/2021

    DOJ publishes guidance on Opioid Use Disorder and the Americans with Disabilities Act April 15, 2022 “The opioid crisis poses an extraordinary challenge to communities throughout our country. The Department of Justice (the Department) has responded with a comprehensive approach prioritizing prevention, enforcement, and treatment. This includes enforcing the Americans with Disabilities Act (Ada), which…

  • Methadone As Normal Medicine

    Admin 03/17/2023

    SUMMARY Methadone prescribing increased tenfold in the last four years in Belgium. This has been made possible through involvement of general practitioners in methadone treatment. Drug overdoses, crime and even presence of methadone on the black market have decreased at the same time. Introduction During the last four years, methadone consumption in Belgium increased tenfold…

  • Risk Factors for HCV

    Admin 03/22/2023

    HCV Info Fact 24 August 2003 The risk factors for Hepatitis C Virus infection are: Intravenous drug use- Current or remote intravenous drug use accounts for 50% of new cases of HVC; 50% to 60% infected with HCV within 3 months of initiation of injection behavior Intranasal cocaine- Risk factor suggested by epidemiologic evidence Tattooing…

  • OBOT Publications

    Admin 04/20/2023

    Publications Office Based Opioid Treatment Federal Code U.S. Federal Code. Confidentiality of Alcohol and Drug Abuse Patient Records. U.S. Federal Code. Medical Privacy HIPPA, National Standards to Protect the Privacy of Personal Health Information. Public Law 106-310, 106th Congress Sec. 3502. Controlled Substances Act, October 17, 2000. Physician Waiver to Prescribe, Dispense Schedule III-V Narcotic Drugs in the…

  • Antiviral Therapy

    Admin 07/04/2021

    HCV Info Fact 9 Nov 2003 Antiviral therapy has steadily improved over the last decade. The side effect profile of interferon-based therapies has remained largely unchanged. Recent data have suggested that improved adherence to combination regimens will favorable affect sustained virologic response rates. The minimal criteria recommended by the National Institutes of Health for candidates…

  • NAMA Organizational Meeting

    Admin 02/13/2022

    Monday, October 18, 2004 One-By-One Just before the meeting the chapters start strolling in. Walking toward the table Howard Lotsof (NAMA), and standing in the doorway is Sharon Dembinski (NE NAMA-MOM) and Barbara Finger (TexNAMA), Charles Kitts (VA NAMA), Cheri Jarvis (VA NAMA) and Paul Bowman (Boston NAMA) discuss chapter issues, sitting at the end…